Clinical Trials Logo

Testicular Germ Cell Tumor clinical trials

View clinical trials related to Testicular Germ Cell Tumor.

Filter by:

NCT ID: NCT06276491 Not yet recruiting - Ovarian Cancer Clinical Trials

Phase 1, Safety and Tolerability Study of XmAb®541 in Advanced Solid Tumors

Start date: May 2024
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate effect of XmAb541 on tumor outcomes.

NCT ID: NCT06133699 Recruiting - Clinical trials for Testicular Germ Cell Tumor

Sentinel Lymph Node Biopsy in Stage AI-IIA Germ Cell Tumors

PITERLAND
Start date: November 8, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate the efficacy of sentinel lymph node biopsy in stage AI-IIA germ cell tumors (seminoma/nonseminoma). The main questions it aims to answer are: - To evaluate relapse-free survival during the first two years after SLNB. - To estimate the percentage of patients who did not require adjuvant treatment after primary endoscopic SLNB. - Determine the microRNA expression profile in blood plasma, evaluate miRNAs as a potential prognostic and predictive factor in patients with testicular germ cell tumors. - Assess the correlation between computed tomography and positive lymph nodes on examination. Participants will undergo: - surgical treatment including orchofuniculectomy with simultaneous laparoscopic biopsy of the sentinel lymph node using indocyanine green dye with/without methylene blue dye. - 24 hours before the procedure, a radiopharmaceutical (RP) is injected into the spermatic cord, followed by SPECT to determine the regional sentinel lymph node(s). - The level of microRNA will be examined before surgery and 10 days after surgery.

NCT ID: NCT05670938 Recruiting - Quality of Life Clinical Trials

Follow-up After Surgery for Testicular Cancer

FUTURE-testis
Start date: November 30, 2022
Phase:
Study type: Observational

The currently developed implementation study aims to evaluate if a patient-led home-based follow-up approach is successful, improves quality of life, reduces anxiety and lessens fear of cancer recurrence during the years after treatment of certain types of testicular cancer.

NCT ID: NCT05238883 Recruiting - Gastric Cancer Clinical Trials

A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

Start date: March 10, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety and tolerability of HFB200301 as a single agent and in combination with tislelizumab in patients with advanced cancers. There are two parts in this study. During the escalation part, groups of participants will receive increasing doses of HFB200301 as a monotherapy or in combination with tislelizumab until a safe and tolerable dose of HFB200301 as a single agent or combination therapy is determined. During the expansion part, participants will take the dose of HFB200301 as a monotherapy or in combination with tislelizumab that was determined from the escalation part of the study and will be assigned to a group based on the type of cancer the participants have.

NCT ID: NCT05063760 Active, not recruiting - Clinical trials for Testicular Germ Cell Tumor

Exercise in Testicular Germ Cell Cancer Survivors

ExCell
Start date: January 15, 2020
Phase: N/A
Study type: Interventional

Regular exercise is effective in prevention & treatment of chronic diseases. Exercise can reduce late toxicity of chemotherapy, commonly found in cancer survivors, which is yet to be translated into clinical practice. Mechanisms of exercise benefits in oncologic patients are far from being elucidated, and include increase in muscle mass, reduction of fat mass, systemic inflammation and cardiometabolic risk. Synchronization of exercise adaptive response is, to an extent, mediated by bioactive molecules released from muscle, with anti-inflammatory & tumor-suppressing properties. Muscle satellite cells are a source of regeneration, muscle structural integrity & functional capacity. Phenotypes of muscle cells, such as secretory profile, lipid & glucose metabolism, mirror clinical phenotypes of the donor. Importantly, muscle cells' metabolism in vitro can be modulated by 8-12 week training in vivo. Epigenetic mechanisms regulating muscle & systemic metabolism in cancer survivors are not yet understood.

NCT ID: NCT05012397 Terminated - Gastric Cancer Clinical Trials

Milademetan in Advanced/Metastatic Solid Tumors

Start date: November 1, 2021
Phase: Phase 2
Study type: Interventional

Phase 2, multicenter, single-arm, open-label basket study designed to evaluate the safety and efficacy of milademetan in patients with advanced or metastatic solid tumors refractory or intolerant to standard-of-care therapy that exhibit wild-type (WT) TP53 and MDM2 copy number (CN) ≥ 8 using prespecified biomarker criteria.

NCT ID: NCT03980587 Recruiting - Clinical trials for Testicular Germ Cell Tumor

Exploratory Study of Molecular Characterization in Patients With Metastatic Germ Cell Tumours Refractory/Resistant to Platinum Treatment

EMIT
Start date: August 2019
Phase:
Study type: Observational

1. To establish whether circulating tumour DNA is detectable in the plasma of patients with platinum refractory/resistant Germ Cell Tumours 2. If ctDNA is detectable, perform exploratory analyses to: 1. Describe the molecular aberrations in plasma from metastatic GCTs with platinum refractory/resistant disease 2. Describe aberrations detected in sequential detected in sequential samples form the same individual patient and evaluate whether there are hyposthesis-generating changes that temporarily associate with clinical resistance.

NCT ID: NCT03448822 Not yet recruiting - Clinical trials for Testicular Germ Cell Tumor

Sentinel Lymph Node Procedure in Testicular Germ Cell Tumour

SENATOR
Start date: September 1, 2018
Phase:
Study type: Observational

Assessment of accuracy of sentinel node biopsy, defined as the false negative rate.

NCT ID: NCT03426865 Active, not recruiting - Clinical trials for Testicular Germ Cell Tumor

Role of Axumin PET Scan in Germ Cell Tumor

TESTPET
Start date: March 1, 2018
Phase:
Study type: Observational

Investigators will use Axumin PET/CT to help with the imaging modalities to determine the presence of occult retroperitoneal disease.

NCT ID: NCT02677727 Completed - Clinical trials for Testicular Germ Cell Tumor

Study of Cisplatin-Induced Peripheral Neuropathy in Patients With Germ Cell Tumor

Start date: July 1, 2015
Phase:
Study type: Observational

This is a prospective observational study investigating the incidence, characteristics of, and change in chronic neuropathy symptoms related to cisplatin using the EORTC CIPN-20 instrument. Approximately 60 patients will be collected for this study. The duration of this study will be up to 18 months for each patient. This study will complement a current R01 funded trial (Platinum Study) which evaluates the genetic predisposition of chronic neuropathy after 12 months of chemotherapy. However, although the platinum study evaluates a similar patient population, it does not evaluate the natural history of platinum induced neuropathy during active treatment and the first 12 months post chemotherapy. This trial will fill this gap and add to the investigators knowledge for both natural history and genetic predisposition of platinum neurotoxicity.